(via TheNewswire)
Each Unit is comprised of one common share in the capital of the Company (each, a "Common Share") and one Common Share purchase warrant (each, a "Warrant"), with each Warrant exercisable at
In connection with the Offering, Voyageur paid cash commissions to qualified non-related parties of
The Company expects to use the gross proceeds from the Offering, net of the cash commissions described above as follows:
Marketing and sales launch
Product testing
Audit and listing / TSXV fees
Corporate G&A (incl. Offering costs)
Total
The Common Shares, Warrants and Broker Warrants issued pursuant to the Offering are subject to a four month hold period from the date of issuance.
About
Voyageur, a Canadian public company trading under the symbol VM on the
Voyageur's business plan is set to generate cash flow by partnering with established third-party GMP pharmaceutical manufacturers in
Voyageur is committed to sustainability and environmental stewardship. The Company envisions a future where carbon neutrality is the norm, and to achieve this, it plans to build state-of-the-art carbon-neutral infrastructure. By investing in carbon neutral energy sources and sustainable manufacturing practices, it aims to become 100% self-sufficient across all its manufacturing activities. Voyageur's commitment to the environment sets it apart as a pioneer in the industry.
At the core of the Company's operations, Voyageur owns a 100% interest in the
Voyageur's ambitious vision is to become the first vertically integrated, carbon-neutral company in the imaging contrast media drug market. By controlling all primary input costs, from the sourcing of raw materials to final production, it plans to ensure unmatched quality and cost efficiency. Voyageur embodies the motto of "From the Earth to the Bottle," highlighting its commitment to responsible sourcing and manufacturing practices.
For Further Information:
Albert | |
Brent@vpharma.ca | Albert@vpharma.ca |
info@vpharma.ca | https://voyageurpharmaceuticals.ca/ |
Neither the
NOT FOR DISSEMINATION IN
Cautionary Statement Regarding “Forward-Looking” Information
This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to the use of proceeds from the Offering, statements with respect to the Company's business plan and the Company's expectation of becoming a high margin domestic manufacturer of radiology drugs, and Voyageur's plans to become self sufficient and vertically integrated, and other statements herein, which expressly or impliedly speak to Voyageur's expectations for its business and operations. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties, including, without limitation, capital market risks and uncertainty, global market factors and supply chain issues, risks relating to the regulation and approval of Voyageur's products, and general risks relating to Voyageur's business. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR+ website at www.sedarplus.ca. Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source